Drawing for HVIVO

USPTO serial 79169697

HVIVO

Reviewed by CopyMark Law Group

Reg. 5815659Status 707Registered
Filing date
Status date
Registration date
Jul 30, 2019
Examiner
TOY, JOSHUA SPENCER JOLL
Law office
Historical data usage

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with HVIVO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Mainak H. Mehta

Mainak H. Mehta Procopio, Cory, Hargreaves & Savitch LLP525 B Street, Suite 2200San Diego, CA 92101United States

Goods and services

ClassDescriptionStatusFirst use
005[ Pharmaceutical and medical compositions for human and/or veterinary use, namely, clinical medical reagents, medical diagnostic reagents, biochemical reagents commonly known as probes for detecting and analyzing molecules in protein or nucleotide arrays; diagnostic preparations and substances for medical purposes; medical diagnostic reagents; antiserums for diagnostic purposes for medical purposes; vaccines for human beings and/or animals; adjuvants for use with vaccines; biological laboratory preparations for medical and/or veterinary purposes, namely, clinical medical reagents, medical diagnostic reagents, biochemical reagents commonly known as probes for detecting and analyzing molecules in protein or nucleotide arrays; chemical preparations for medical, pharmaceutical and veterinary purposes, namely, clinical medical reagents, medical diagnostic reagents, biochemical reagents commonly known as probes for detecting and analyzing molecules in protein or nucleotide arrays; chemical reagents for medical, pharmaceutical and veterinary purposes; viruses for the treatment of humans and/or animals, namely, viruses for use as an ingredient in vaccines for preventing and treatment of influenza or HRV or RSV; diagnostic preparations for medical purposes; in-vitro diagnostic reagents for medical purposes; in-vivo reagents for diagnostic medical purposes ]SECTION 71 - CANCELLED—
035Business investigation and research services relating to cost and business efficiency, all relating to pharmaceuticals, medicine, medicines, vaccines, science, bacteriology, toxicology, chemistry, clinicology, oncology, biochemistry and biotechnology; systemization and compilation of medical information into computer databases; providing statistical information for business purposes, all of said information relating to pharmaceuticals, medicine, medicines, vaccines, science, bacteriology, toxicology, chemistry, clinicology, oncology, biochemistry and biotechnology; registration services for diagnostic testing, namely, services consisting of the registration, collection, transcription, compilation and systemization of written communications and data with respect to diagnostic testing; product demonstration services in the field of diagnostic testing; computer database management services, including information storage and retrieval services in the fields of diagnostic testing and preparations for the treatment, monitoring or diagnosis of disease; trade information services in the fields of medical, health, or clinical care; database management of diagnostic testing and results, database management of medical, hospital, insurance or billing records; collation and provision of business information for the purpose of providing referral services in the fields of medical, health or clinical care; collation and provision of business information regarding results from diagnostic testing in relation to medicine and pharmacy; collation and provision of business information regarding medical and pharmaceutical testing procedures; collation and provision of business information regarding disease conditions and disease prevention; collation and provision of business information regarding medical, hospital, insurance or billing recordsACTIVE—
042Medical research services; conducting clinical trials for others; medical research laboratory services; scientific analysis and research services, namely scientific research; product development relating to pharmaceuticals, medicines, medicaments and veterinary products; medical and health care research services in the field of clinical testing services, physician testing services for assisting pharmacists, pharmacy testing services, medical laboratory and testing services; medical research into the causes and treatment of influenza and the common cold; research services in the field of medical diagnostics; medical laboratory services for the analysis of samples taken from patients for research purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 22, 2026NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
May 22, 202671.PREGISTERED - PARTIAL SEC 71 ACCEPTED—
May 18, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jan 20, 2026ES71TEAS SECTION 71 RECEIVED—
May 1, 2025RNWLINTERNATIONAL REGISTRATION RENEWED—
Jul 30, 2024REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Nov 30, 2019FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Nov 6, 2019FICSFINAL DISPOSITION NOTICE SENT TO IB—
Nov 6, 2019FIMPFINAL DISPOSITION PROCESSED—
Oct 30, 2019FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jul 30, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 31, 2019GPNXNOTIFICATION PROCESSED BY IB—
May 14, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 14, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 9, 2019NREPNEW REPRESENTATIVE AT IB RECEIVED—
Apr 24, 2019OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Apr 24, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 24, 2019OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Apr 2, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 21, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 21, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 21, 2019ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Nov 2, 2018RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
May 1, 2018RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Oct 20, 2017RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Apr 19, 2017RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jan 20, 2017OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jan 4, 2017OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jan 4, 2017OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Oct 13, 2016RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Apr 7, 2016RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Mar 22, 2016ALIEASSIGNED TO LIE—
Sep 22, 2015GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Sep 22, 2015GNSLLETTER OF SUSPENSION E-MAILED—
Sep 22, 2015CNSLSUSPENSION LETTER WRITTEN—
Sep 18, 2015RFNTREFUSAL PROCESSED BY IB—
Sep 18, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 17, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 17, 2015TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 27, 2015RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Aug 27, 2015RFRRREFUSAL PROCESSED BY MPU—
Aug 27, 2015RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Aug 26, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 13, 2015DOCKASSIGNED TO EXAMINER—
Aug 11, 2015MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 6, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 30, 2015REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance